In this task, you're given a paragraph and title from the research paper. Your task is to classify whether the given title is suitable or not for the research paper based on the given paragraph. Return "True" if title is proper according to paragraph else "False".

Ex Input:
Paragraph: We characterized DBD by measuring concentrations of reactive species and ions. The inactivation efficiency was deduced using aerosol-and colony-counting methods. Susceptibility constant (Z) was introduced for performance evaluation of DBD. Modified Z was suggested for evaluation of DBD reactors of different sizes. Our methodology will be used for design optimization and performance evaluation. Dielectric barrier discharge (DBD) is a promising method to remove contaminant bioaerosols. The collection efficiency of a DBD reactor is an important factor for determining a reactor's removal efficiency. Without considering collection, simply defining the inactivation efficiency based on colony counting numbers for DBD as on and off may lead to overestimation of the inactivation efficiency of the DBD reactor. One-pass removal tests of bioaerosols were carried out to deduce the inactivation efficiency of the DBD reactor using both aerosol-and colony-counting methods. Our DBD reactor showed good performance for removing test bioaerosols for an applied voltage of 7.5 kV and a residence time of 0.24 s, with Á CFU , Á Number , and Á Inactivation values of 94%, 64%, and 83%, respectively. Additionally, we introduce the susceptibility constant of bioaerosols to DBD as a quantitative parameter for the performance evaluation of a DBD reactor. The modified susceptibility constant, which is the ratio of the susceptibility constant to the volume of the plasma reactor, has been successfully demonstrated for the performance evaluation of different sized DBD reactors under different DBD operating conditions. Our methodology will be used for design optimization, performance evaluation, and prediction of power consumption of DBD for industrial applications. 
 Title: Susceptibility constants of airborne bacteria to dielectric barrier discharge for antibacterial performance evaluation

Ex Output:
False


Ex Input:
Paragraph: Purpose of review-New respiratory viruses have been discovered in recent years and new molecular diagnostic assays have been developed that improve our understanding of respiratory virus infections. This article will review the changing epidemiology of these viruses after hematopoietic stem cell and solid organ transplantation. Recent findings-Respiratory viruses are frequently detected in transplant recipients. A number of viruses have been newly discovered or emerged in the last decade, including human metapneumovirus, human bocavirus, new human coronaviruses and rhinoviruses, human polyomaviruses, and a new 2009 pandemic strain of influenza A/H1N1. The potential for these viruses to cause lower respiratory tract infections after transplantation varies, and is greatest for human metapneumovirus and H1N1 influenza, but appears to be limited for the other new viruses. Acute and long term complications in hematopoietic and solid organ transplant recipients are active areas of research. Summary-Respiratory viral infections are frequently associated with significant morbidity following transplantation and are therefore of great clinical and epidemiologic interest. As new viruses are discovered, and more sensitive diagnostic methods are developed, defining the full impact of emerging respiratory viruses in transplant recipients must be elucidated by welldesigned clinical studies. 
 Title: Changing Epidemiology of Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients and Solid Organ Transplant Recipients

Ex Output:
False


Ex Input:
Paragraph: The most recent Ebola virus outbreak in West Africa -unprecedented in the number of cases and fatalities, geographic distribution, and number of nations affected -highlights the need for safe, effective, and readily available antiviral agents for treatment and prevention of acute Ebola virus (EBOV) disease (EVD) or sequelae 1 . No antiviral therapeutics have yet received regulatory approval or demonstrated clinical efficacy. Here we describe the discovery of a novel anti-EBOV small molecule antiviral, GS-5734, a monophosphoramidate prodrug of an adenosine analog. GS-5734 exhibits antiviral activity against multiple variants of EBOV in cell-based assays. The pharmacologically active nucleoside triphosphate (NTP) is efficiently formed in multiple human cell types incubated with GS-5734 in vitro, and the NTP acts as an alternate substrate and RNAchain terminator in primer-extension assays utilizing a surrogate respiratory syncytial virus RNA polymerase. Intravenous administration of GS-5734 to nonhuman primates resulted in persistent Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com 
 Title: Therapeutic Efficacy of the Small Molecule GS-5734 against Ebola Virus in Rhesus Monkeys

Ex Output:

True